Reviews
No OS Difference With Primary Endocrine Therapy vs Surgery in ER-Positive Breast Cancer
Carleton et alJAMA network open

In a systematic review and meta-analysis evaluating older women with operable, nonmetastatic, estrogen receptor (ER)-positive breast cancer, primary endocrine therapy (pET) was evaluated against upfront surgery to assess survival outcomes and variables associated with response duration. A search of PubMed, MEDLINE, Web of Science, and the Cochrane Central Register of Controlled Trials through March 26, 2026, identified 29 studies (6 randomized clinical trials [RCTs] and 23 observational cohorts) comprising 22,821 patients with an overall median age of 83.1 years (IQR, 77.0-85.0 years). Patients enrolled in RCTs were generally younger (median age, 77.0 years; IQR, 75.8-78.0 years) than those in observational studies (median age, 84.0 years; IQR, 81.5-86.0 years).
Pooled analysis of the RCTs using a random-effects model showed that pET was not associated with a statistically significant difference in overall survival compared with surgery (HR, 1.14; 95% CI, 0.98-1.33), although the point estimate favored surgical management. Observational cohorts were analyzed descriptively rather than pooled due to potential confounding by indication. Across these cohorts, median time to progression ranged from 19.7 months (range, 13.5-26.0 months) in tumor biology-unselected, tamoxifen-era cohorts to more than 50 months in ER-selected and aromatase inhibitor-treated cohorts. Tumor biology was consistently associated with progression risk, and durable disease control under pET seemed to be concentrated among patients with favorable biology. The authors conclude that these data support using a decision-making framework based on tumor biology and frailty rather than age or life expectancy alone when considering pET.
Key Takeaways
- In pooled randomized clinical trials, primary endocrine therapy was not associated with a statistically significant overall survival difference compared with upfront surgery (HR, 1.14; 95% CI, 0.98-1.33), though the point estimate favored surgery.
- Median time to progression ranged from 19.7 months (range, 13.5-26.0 months) in tumor biology-unselected, tamoxifen-era cohorts to more than 50 months in estrogen receptor-selected and aromatase inhibitor-treated cohorts.
- These findings support incorporating tumor biology and frailty rather than chronological age alone to guide patient selection for primary endocrine therapy.
Read the original sourceJAMA network open
